Funding for Arctic’s anti-amyloid treatment for rare and common forms of dementia

Icelandic drug discovery and development company Arctic Therapeutics (ATx) has announced the successful closing of a 26.5 million euros ($27.7 million) oversubscribed Series A financing from a broad syndicate of investors.

Proceeds from the round will be used to advance ATx’s two frontrunners, AT-001 and AT-004, further into the clinic. 

Last year, the European Medicines Agency (EMA) approved a pivotal Phase IIb/III trial evaluating AT-001 for the treatment of hereditary cystatin C amyloid angiopathy (HCCAA), a rare form of familial dementia.